Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajeshwari Sridhara

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Statistical Methods in Medical Research|February 21, 2008
Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issuesAloka Chakravarty, Rajeshwari Sridhara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015Susan Jin, Richard Pazdur, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2017
Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical StudiesXin Gao, Lijun Zhang, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2018
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy TrialsSirisha L Mushti, Flora Mulkey, Rajeshwari Sridhara
Therapeutic Innovation & Regulatory Science|May 2, 2018
Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000Susan Jin, Pallavi S Mishra-Kalyani, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2013
Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trialsRajeshwari Sridhara, Sumithra J Mandrekar, Lori E Dodd
Therapeutic Innovation & Regulatory Science|September 20, 2018
Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation StudyLijun Zhang, Chia-Wen Ko, Shenghui Tang, et al.
Pharmaceutical Statistics|June 16, 2020
A Bayesian approach in design and analysis of pediatric cancer clinical trialsJingjing Ye, Gregory Reaman, R Angelo De Claro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapyRobert C Kane, Ann T Farrell, Rajeshwari Sridhara, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast CancerErik Bloomquist, Susan Jin, Jiaxi Zhou, et al.
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Statistical Methods in Medical Research|February 21, 2008
Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issuesAloka Chakravarty, Rajeshwari Sridhara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015Susan Jin, Richard Pazdur, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2017
Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical StudiesXin Gao, Lijun Zhang, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2018
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy TrialsSirisha L Mushti, Flora Mulkey, Rajeshwari Sridhara
Therapeutic Innovation & Regulatory Science|May 2, 2018
Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000Susan Jin, Pallavi S Mishra-Kalyani, Rajeshwari Sridhara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2013
Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trialsRajeshwari Sridhara, Sumithra J Mandrekar, Lori E Dodd
Therapeutic Innovation & Regulatory Science|September 20, 2018
Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation StudyLijun Zhang, Chia-Wen Ko, Shenghui Tang, et al.
Pharmaceutical Statistics|June 16, 2020
A Bayesian approach in design and analysis of pediatric cancer clinical trialsJingjing Ye, Gregory Reaman, R Angelo De Claro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapyRobert C Kane, Ann T Farrell, Rajeshwari Sridhara, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast CancerErik Bloomquist, Susan Jin, Jiaxi Zhou, et al.
Pageof 13